Open AccessGenome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer
Author(s) -
Lee Jieun,
Choi Ahyoung,
Cho SungYup,
Jun Yukyung,
Na Deukchae,
Lee Ahra,
Jang Giyong,
Kwon Jee Young,
Kim Jaesang,
Lee Sanghyuk,
Lee Charles
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12853
Subject(s) - erlotinib , cancer research , biology , epidermal growth factor receptor , lung cancer , erlotinib hydrochloride , cancer , medicine , genetics , oncology
Here, we discovered that targeting cell cycle processes or protein ubiquitination pathways are promising treatment strategies for overcoming resistance to EGFR inhibitors in lung cancer using a genome‐scale CRISPR‐Cas9 screening. Combination therapies targeting each of these two processes such as nutlin‐3 and carfilzomib increased cancer cell death when combined with erlotinib in both in vitro and in vivo experiments.